Meatable

Market position

Meatable was among Europe's most visible cultivated meat developers and one of the leading companies focused on cultivated pork, claiming the fastest cell differentiation timeline in the industry. It was named to Time magazine's best inventions of 2024 and was the first company to host a legally approved cultivated meat tasting in the European Union. Its shutdown followed those of Believer Meats, CellRev and Upstream Foods amid a sharp contraction in cultivated meat funding, which fell to $36 million across the sector in the first nine months of 2025 from $139 million in 2024.

Meatable's principal technical differentiator was the use of pluripotent stem cells with opti-ox technology and a perfusion process, which it said allowed differentiated muscle and fat cells to be produced in as little as four days — described as the fastest timeline of any company in the sector — without the immortalised cell lines used by many peers and without fetal bovine serum. The company claimed 100% differentiation efficiency and argued the speed would let it reach cost parity with conventional meat.

Technology

The company's platform combined patented opti-ox technology with pluripotent stem cells, which it described as the only method to grow real muscle and fat cells from PSCs at speed and with 100% efficiency. Unlike immortalised cell lines, PSCs multiply naturally and rapidly; coupled with a perfusion process enabling a continuous cycle and very high cell densities, Meatable said it could produce fully differentiated muscle and fat cells in four days (eight days as described in 2023). It also eliminated fetal bovine serum, reporting in 2018 that it had grown meat using pluripotent stem cells from animal umbilical cords. Production ran in 200-litre bioreactors in Leiden, with potential expansion to 500 litres. The 2025 acquisition of Uncommon Bio's platform added intellectual property, cell lines and RNA-enabled reprogramming and differentiation technologies intended to support expansion beyond pork and beef into chicken and lamb.

Go-to-market

Meatable planned a phased market entry beginning with Singapore, launching in selected restaurants and retailers from 2024 subject to approval, then extending to the United States and other markets as regulations allowed. It used public-facing activities to build industry relationships, including a public tasting in the EU in April 2024 and a global summit at its Leiden headquarters in February 2025 for policymakers, investors and food and meat industry leaders, and it framed its technology as adding capacity to conventional meat supply chains rather than replacing them.

Restaurants and retailers as initial channels for cultivated pork products, alongside conventional meat industry partners and processors; the Pelagen partnership extended the technology to cell-based leather applications.

Geography

Headquartered in the Netherlands — initially on the Delft University of Technology campus in Delft and later in Leiden, where it operated its laboratory and bioreactor facility. Singapore was its intended first commercial and regulatory market, including a planned cultivated meat factory with TruMeat and manufacturing via ESCO Aster; it also pursued market entry in the United States and participated in the UK regulatory sandbox.

History

After its 2018 founding in Delft, Meatable raised €3.5 million in October 2018 and presented at CES in January 2020, aiming for proof of concept by year-end. In 2021 it raised €40 million (about $47 million), bringing total capital to roughly €53 million (about $60 million), grew past 40 staff, and signed an agreement with DSM to help make cultured meat affordable at scale. In August 2023 it closed a $35 million round led by Agronomics, taking total funding to $95 million, to scale processes and prepare a commercial launch in Singapore. In April 2024 it hosted the EU's first legally approved cultivated meat tasting, was awarded €7.6 million under the Netherlands Enterprise Agency's Innovation Credit programme, partnered with Desmos Capital Partners on a €30 million capital placement, and secured strategic investment from Betagro Ventures. Jeff Tripician was appointed CEO in May 2024. In February 2025 it held a global summit at its Leiden headquarters, in August 2025 it acquired Uncommon Bio's cultivated meat platform, and during 2025 it teamed with TruMeat on a planned Singapore facility. On 19 December 2025 Agronomics announced that Meatable would be wound down and dissolved after failing to secure further funding.

Risks & controversies

Meatable's business depended on regulatory approvals it never received: clearance in Singapore, anticipated by the first quarter of 2025, was still pending when the company closed, leaving it unable to generate revenue. A collapse in cultivated meat investment — sector funding of $36 million in the first nine months of 2025 versus $139 million in 2024 — left the company unable to close an approximately $35 million Series C, and it failed to secure continued backing from existing or new investors. Agronomics cited foreseeable and unforeseeable risks and uncertainties throughout 2025 that impaired execution of Meatable's strategy, and wrote its £11.9 million holding down to zero.